BD to Invest $35M to Grow Nebraska Syringe Manufacturing

BD (Becton, Dickinson and Company) will invest over $35 million and add about 50 new jobs to expand prefilled flush syringe manufacturing at its Columbus, Neb. facility.

The investments will support new BD PosiFlush prefilled flush syringe production lines, product innovation, and operational efficiencies. It will allow the company to produce hundreds of millions of additional units to meet U.S. hospital and health system demand.

Prefilled flush devices are used in almost every hospital in the country as part of catheter care and maintenance, and prevent catheter-related complications. Quality in manufacturing these devices is critical because the deliver fluid directly into the bloodstream, where any contamination or defect can have serious, even fatal, consequences.

PosiFlush syringes, according to BD, are manufacturing using a fully automated, hands-free process. This way, it’s ensured the first person to touch the syringe is the clinician. Each syringe is inspected using a multi-step inspection process to meet high quality standards.

BD has invested over $80 million over the past three years to expand PosiFlush capacity, growing U.S. production by more than 750 million units—including a 10% increase this year. The company’s Columbus facility is the largest manufacturer of prefilled flush devices in the U.S. and has been in operation for over 75 years.

“BD PosiFlush Syringes are essential to everyday patient care for keeping catheters clear and safely delivering medications,” said Eric Borin, worldwide president of BD Medication Delivery Solutions. “Our latest investments boost U.S. production capacity and reinforce our commitment to a reliable supply for health care providers and the patients they serve.”

Earlier this year, the company revealed it will invest $2.5 billion in U.S. manufacturing capacity over the next five years. This includes over $40 million in investments in the U.S. to expand capacity for syringes, needles, and IV catheters.